Citius Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Citius Pharmaceuticals

22/12/2022 22:06

* Citius Pharmaceuticals Inc  CTXR.OQ  reported a quarterly
adjusted loss of 5 cents​​ per share for the quarter ended in
September. The mean expectation of three analysts for the
quarter was for a loss of 4 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Citius Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 5 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Citius Pharmaceuticals Inc shares had fallen by 14.9% this
quarter and lost 33.1% so far this year.
    * The company reported a quarterly loss of $7.99 million.
    * Wall Street's median 12-month price target for Citius
Pharmaceuticals Inc is $8.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data December
22 at 10:06 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.04          -0.05          Missed
 Jun. 30 2022      -0.05          -0.06          Missed
 Mar. 31 2022      -0.07          -0.05          Beat
 Dec. 31 2021      -0.06          -0.06          Met